Acute lymphoblastic leukemia subsequent to temozolomide use In a 26-year-old man: A case report

Journal of Medical Case Reports

Volumn 4, Issue 1, 2010, Pages

  Shaikh, Asim Jamal ^a   Masood, Nehal ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD3 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; RECEPTOR TYPE TYROSINE PROTEIN PHOSPHATASE C; TEMOZOLOMIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADJUVANT THERAPY; ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER ADJUVANT THERAPY; CANCER INFILTRATION; CAPILLARY RESISTANCE; CASE REPORT; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CYTOPLASM; DRUG WITHDRAWAL; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; LYMPHOCYTE; MALE; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL; NUCLEAR MAGNETIC RESONANCE IMAGING; PLATELET COUNT; PRIORITY JOURNAL; RADIATION DOSE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 85040673800     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-4-274     Document Type: Article

References (12)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
2. Su YW, Chang MC, Chiang MF, Hsieh RK: Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neuro-oncol 2005, 71:315-318.
3. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S: Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003, 21:897-906.
4. Macdonald DR: Temozolomide for recurrent high-grade glioma. Semin Oncol 2001, 28:12.
5. Noronha V, Berliner N, Ballen KK, Lacy J, Kracher J, Baehring J, Henson JW: Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro-oncology 2006, 8:280-283.
6. De Vita S, De Matteis S, Laurenti L, Chiusolo P, Reddiconto G, Fiorini A, Leone G, Sica S: Secondary Ph+ acute lymphoblastic leukemia after temozolomide. Ann Hematol 2005, 84:760-762.
7. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
8. Darkes M J M, Plosker GL, Jarvis B: Temozolomide a review of its use in the treatment of malignant gliomas. Am J Cancer 2002, 1:55-80.
9. Villano JL, Seery TE, Bressler LR: Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol 2009, 64:647-655.
10. Hau P, Koch D, Hundsberger T, Marg E, Bauer B, Rudolph R, Rauch M, Brenner A, Rieckmann P, Schuth J, et al: Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 2007, 68:688-690.
11. Clinical Trials.gov. [http://clinicaltrials.gov/ct2/results?term=temozolomide].
12. Geiger H, Schleimer D, Nattamai KJ, Dannenmann SR, Davies SM, Weiss BD: Mutagenic potential of temozolomide in bone marrow cells in vivo. Blood 2006, 107:3010-3011.